Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-Hopitaux De Paris

Ariana Pharmaceuticals

Other

Bio-Rad Europe Gmbh

Bio-Rad Innovations

Université Paris Diderot-Paris 7

Isabelle Catherine Batxelli

Tarik Asselah

Bénédicte Watelet

Mohammad Afshar

Patrick Marcellin

Nathalie Jullian

Ivan Bieche

Michel Vidaud

Daniel Laune

Eve Laure Mathieu

Benedicte Watelet

Nadine Lambert

Eve Mathieu Dupas

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:

Combination of biomarkers for detecting and evaluating a hepatic fibrosis

The application relates to hepatic fibrosis, specifically to hepatic fibrosis that may appear in a patient infected with one or more hepatitis viruses and/or who is suffering from hepatitis, specifically chronic hepatitis. The application provides methods and means for determining the stage (or degree) of hepatic fibrosis of such a patient. Specifically, the methods and means of the application make it possible to determine whether or not the stage (or degree) of hepatic fibrosis of the patient has exceeded the stage of light fibrosis. The methods and means of the invention use a combination of biomarkers such as, in particular, the CXCL10 protein and hyaluronic acid (HA).

Synergistic combination of biomarkers for detecting and assessing hepatic fibrosis

The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being:

Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment

Combination of biomarkers for the detection and evaluation of hepatitis fibrosis

Growing community of inventors

Aigues-Vives, France

Isabelle Catherine Batxelli